Stivarga (regorafenib) is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had Nexavar (sorafenib), but only if they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
This means they are fully active and able to carry on all pre-disease performance without restriction or they are restricted in physically strenuous activity but able to carry out work of a light or sedentary nature.
According to NICE, a few hundred patients each year will benefit from the decision, which marks a turnaround from a guidance published earlier in the year which rejected the drug…
